Aiforia Technologies Oyj Anticipates Strong Clinical Revenue Growth

Aiforia Technologies Oyj projects a significant boost in clinical revenue growth, as highlighted in NuWays AG's recent research. The company's upcoming H2'25 results are set to reveal a 47% year-over-year sales increase, reaching €2.18 million. Clinical revenue is expected to accelerate by 70% sequentially, a notable increase from the 60% growth seen in H1'25.

The clinical segment remains the primary focus for scaling business, supporting the modest growth expectations for the Research segment in H2'25. The research anticipates a compound annual growth rate of 84% for the Clinical segment from FY26 to FY28, propelled by strategic partnerships and the adoption of pathology AI technology.

Additionally, Aiforia's profitability is set to improve in H2'25, with EBITDA expected to reach €-2.7 million. The company’s recent workforce reductions aim to save €2.5 million annually starting FY26, ensuring a solid cash runway through FY26.